More about ENZAMET
Doctors commonly start men newly diagnosed with metastatic prostate cancer on androgen deprivation therapy (otherwise known as ADT), along with a standard anti-androgen tablet (such as Cosudex or Anandron). These drugs work in prostate cancer by shutting off the supply of testosterone, which is the fuel that drives prostate cancer growth. While this standard treatment is very effective, doctors and researchers are constantly striving for ways to improve treatment and increase patient survival from metastatic prostate cancer. The striking results from the ENZAMET clinical trial, presented at the Plenary Session of the 2019 American Society of Clinical Oncology (ASCO) meeting, and published in the New England Journal of Medicine, have achieved just that.
ENZAMET is a large Phase 3 study that shows that giving enzalutamide along with ADT to “hormone-naïve” men (who are just starting ADT) reduced the risk of death at 3-years by a third, relative to giving ADT with the standard anti-androgen drug. Enzalutamide also significantly increased the time until the cancer showed signs of growing, either by symptoms, scans, or rising PSA. Before these findings, enzalutamide was given only to men with metastatic prostate cancer after ADT stopped working. This study now suggests that enzalutamide should be considered much earlier in the course of the disease, around the time of starting ADT when patients are diagnosed with metastatic cancer.
The ENZAMET trial began in 2014 and recruited 1125 patients from 83 medical centres around the world. Men with metastatic prostate cancer starting first-line ADT were enrolled in the study. The average age of the men in the study was 69 years; 11% of men had metastatic disease outside of the bones and lymph nodes. The study is led by the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group.
The positive findings from the ENZAMET trial will mean that once Enzalutamide is available, men with metastatic prostate cancer will have another treatment option.
For further details on the ENZAMET trial results, as presented at the 2019 ASCO Plenary in Chicago, please view the ENZAMET Press Release.